For prescription drug addiction treatment, buprenorphine maintenance trumps detoxification

21 Oct 2014

1

For treating patients with prescription-opioid dependence in primary care,buprenorphine maintenance therapy is superior to detoxification, according to a new study by Yale School of Medicine researchers published in the 20 October issue of JAMA Internal Medicine.

Prescription-opioid dependence has been increasing for the last 15 years and now surpasses heroin-dependence. Doctors are also writing more prescriptions for pain management, which has led to higher experimentation and addiction rates, according to lead author Dr. David Fiellin, professor of internal medicine at Yale School of Medicine.

''Primary care physicians lack evidence-based guidelines to decide between detoxification or providing patients with ongoing maintenance therapy,'' said Fiellin.

Fiellin and his colleagues conducted a 14-week randomised clinical study of 113 patients with prescription opioid dependence. Patients randomly received either buprenorphine detoxification or ongoing buprenorphine maintenance therapy.

Buprenorphine is a medication used to treat addiction. Study participants in the detoxification group received six weeks of stable doses of buprenorphine followed by three weeks of tapering doses.

All patients received physician and nurse support and drug counseling for all 14 weeks.

The team found that patients in the detoxification group tested positive for illicit opioid use more often than those in the maintenance group.

Patients who received ongoing buprenorphine were less likely to use illicit opiates. Few of the patients in the detoxification group stayed in treatment or were able to abstain after the medication was discontinued.

''For prescription opioid dependence, buprenorphine detoxification is less effective than ongoing maintenance treatment, and increases the risk of overdose and other adverse events,'' said Fiellin. ''We found that a number of providers were offering patients buprenorphine detoxification. This is not consistent with how the disease process works.''

''It is very common for patients seeking treatment to request detoxification,'' said Fiellin. ''They want to be off of everything as soon as possible as opposed to considering long-term treatment, but unfortunately there's no quick fix for the disease. The majority of patients will do better if they receive ongoing maintenance treatment.''

Other authors of the study included Richard Schottenfeld, M.D., Christopher J. Cutter, Brent A. Moore, Declan T. Barry, and Patrick G. O'Connor, M.D.

The National Institute on Drug Abuse funded the study.

Latest articles

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

Toyota set for third straight quarterly profit drop as costs and tariffs weigh

Toyota set for third straight quarterly profit drop as costs and tariffs weigh